ABVX:EPA
Abivax SA
77,15 €
arrow_downward
-0,64%(-0,50) 1D
6 nën, 5:36:06 m.d., GMT+1 · EUR
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për ABVX...
Hap
74,45 €
I lartë
77,15 €
I ulët
73,80 €
Kapitalizimi i tregut
6,84 mld
Vëllimi mesatar
111,44 mijë
Vëllimi
161,37 mijë
Maksimumi 52-javor
139,00 €
Minimumi 52-javor
60,45 €
Fitimet për aksion
-5,20 €
Aksionet në qarkullim
87,55 mln
Numri i punonjësve
98
Hap
74,45 €
I lartë
77,15 €
I ulët
73,80 €
Kapitalizimi i tregut
6,84 mld
Vëllimi mesatar
111,44 mijë
Vëllimi
161,37 mijë
Maksimumi 52-javor
139,00 €
Minimumi 52-javor
60,45 €
Fitimet për aksion
-5,20 €
Aksionet në qarkullim
87,55 mln
Numri i punonjësve
98
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Nasdaq
·
1 orë më parë
Chartstopper: November 6, 2026
qz.com
·
1 orë më parë
NYSE market strategist Eric Criscuolo makes sense of eventful Wall Street week
The Detroit News
·
1 orë më parë
Stagwell Inc. (STGW) Reports Equity Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Investing.com
·
19 minuta më parë
Auddia announces warrant exchange agreements for common stock on Nasdaq
Profili
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Rreth Abivax SA
Drejtori ekzekutivMarc de Garidel | Hartmut J. Ehrlich
Punonjësit98
Themeluar më4 dhj 2013
Selia-
SektoriHealth Care
Industria-
Uebsajtiabivax.com